3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
5
Phase 4
1
Phase 3
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Myeloid
1
Conditions
Myeloproliferative Disorders
1
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
1
Blast Crisis
1
Interventions
Magnetic Resonance Spectroscopy
3
Specimen Handling
2
Papillomavirus Vaccines
2
Lenalidomide
2
Immune Checkpoint Inhibitors
2
Imatinib Mesylate
2
Human Papillomavirus Recombinant Vaccine nonavalent
2
Diosmin
2
Dexamethasone
2
venetoclax
1
trametinib
1
tocilizumab
1
sofosbuvir-velpatasvir drug combination
1
semaglutide
1
ruxolitinib
1
rozanolixizumab
1
rasburicase
1
radium Ra 223 dichloride
1
pyrotinib
1
pirtobrutinib
1
oxycodone-acetaminophen
1
obinutuzumab
1
nirogacestat
1
nilotinib
1
ixazomib
1
idelalisib
1
human papillomavirus vaccine, L1 type 16, 18
1
fluciclovine F-18
1
darolutamide
1
dabrafenib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 4
×
nilotinib
×
30 days
×
Clear all
NCT04877522
2026-05-11
Asciminib Roll-over Study
Novartis
Phase 4
Recruiting
347 enrolled